Smart monitoring for men with advanced prostate cancer
Part of Cancer clinical trials.
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have prostate cancer that has spread to other parts of the body (metastatic).
- Your cancer is sensitive to hormones—meaning it can be treated with hormone therapy.
- Your testosterone level is above 50 ng/dL before starting hormone therapy.
- Your PSA is at least 1 ng/mL before starting therapy for metastatic disease.
- You have a smartphone and are comfortable using health apps.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial is testing whether giving prostate removal surgery in addition to standard hormone therapy can help men with advanced prostate cancer that has spread to many places. It aims to see if this combination helps them live longer with a better quality of life.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests a new way to predict how well hormone therapy combined with newer drugs works for men with prostate cancer that has spread. It uses advanced tissue analysis to help tailor treatment.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.